A head-to-head study of 4 commonly used field-directed treatments.

Bermekimab may represent an important new treatment for pruritus and moderate-to-severe AD.

Results from a 5-year extension study of the phase 3 ERASURE and FIXTURE trials.

Association is seen even among patients with mild and inactive disease.

In a new study, virtually all patients with moderate to severe atopic dermatitis had symptoms of anxiety and depression.

Substantial geographic variation observed, suggesting need for optimized use.

Efficacy was similar to that reported in clinical trials.

Few studies have assessed interventions sufficiently.

Real-world data show similar efficacy for atopic dermatitis but higher incidence of adverse events.

Analysis suggests readmission is common and costly.

Results of a national survey.

Good efficacy for moderate acne in patients aged 9 years and older.

No prevention, but potential for protection.

Pooled analysis of the phase 3 LIBERTY AD SOLO 1 and 2 trials.